Radiotherapy for Extramedullary Leukaemic Manifestation (Chloroma)
Overview
Affiliations
Purpose: Extramedullary leukaemic disease (EMD, synonym chloroma) is a rare solid manifestation of myeloid leukaemia for which the value of radiotherapy (RT) as a treatment strategy remains controversial. The aim of this study is to analyse the effectiveness of various RT doses for EMD in the modern treatment era.
Materials And Methods: Between January 2000 and June 2016, 20 patients with total of 45 lesions underwent RT for EMD at our institution.
Results: With a median radiation dose of 26 Gy (range 4-42 Gy), local remission could be achieved in 91% of patients (complete remission rate: 71%). The median duration of local control (DOLC) was 17 months (95% confidence interval [CI] 0.5-33) and the median overall survival (OS) after chloroma onset was 24 months (95% CI 11-38). No noticeable difference between high- and low-dose regimens has been observed (74% versus 68%; P = 0.5). In the multivariate analysis, only Eastern Cooperative Oncology Group (ECOG) score and bone marrow state during RT have proven to be determinant for durable local control and OS.
Conclusions: Low-dose RT (≤26 Gy) achieves good local control compared to high-dose regimes. Bone marrow state during RT and ECOG score during RT may play a crucial role, influencing both DOLC and OS.
A case of relapsed acute myeloid leukemia mimicking acute otomastoiditis.
Negara I, Chemencedji I, Dobrovolschi N, Sporis N, Buruiana S, Vinogradov I Clin Case Rep. 2024; 12(4):e8717.
PMID: 38550726 PMC: 10965747. DOI: 10.1002/ccr3.8717.
Hoffmann E, Boke S, De-Colle C, Lengerke C, Niyazi K, Gani C Strahlenther Onkol. 2024; 200(10):908-915.
PMID: 38285172 PMC: 11442554. DOI: 10.1007/s00066-024-02200-2.
Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse.
Beziat G, Tavitian S, Arnaud F, Izar F, Attal J, Borel C J Contemp Brachytherapy. 2023; 14(6):601-604.
PMID: 36819473 PMC: 9924153. DOI: 10.5114/jcb.2022.123980.
Xing Z, Zhu X, Li Z, Wang H, Qian M, Zhai X Front Oncol. 2022; 12:989366.
PMID: 36059682 PMC: 9433649. DOI: 10.3389/fonc.2022.989366.
Fontanesi J, Margolis H, Fontanesi G J Family Med Prim Care. 2020; 9(7):3741-3744.
PMID: 33102361 PMC: 7567292. DOI: 10.4103/jfmpc.jfmpc_22_20.